Carl Zeiss Meditec : Q3 numbers due 5 August – likely to be better than initially feared
>China to have recovered during the course of Q3 - Carl Zeiss Meditec is the company with the highest exposure to China in our healthcare coverage universe (estimated c. 25-30% of sales). Moreover, the increasing importance of China with the number of refractive surgery procedures also increasing in this country helped the group EBIT margin to expand from c. 14% in 2016 to 18% in 2019. While the lockdowns in China, in particular in the Shenzhen and Shanghai regions, e...Carl Zeiss Meditec is a holding company. Co.'s businesses are focused on two primary areas: Ophthalmology and Microsurgery. In Ophthalmology, Co.'s operations are divided in to two strategic business units: Ophthalmic Systems, which includes a range of laser and diagnostic systems for ophthalmology; and Surgical Ophthalmology, which consists of activities in the field of ophthalmic implants and consumables. In Microsurgery, Co. provides surgical microscopes and visualization solutions, e. g. for ear, nose and throat surgery, or neurosurgery. These products are mainly used to assist with the removal of tumors, as well as the treatment of vascular diseases and functional disorders.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.